- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000988
A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex
A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
To evaluate the safety, minimum effective dose (MED), pharmacokinetics and efficacy of orally administered 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) in patients with AIDS or AIDS related complex (ARC). To establish an appropriate dosage regimen of d4T to be employed in Phase II and III trials. To evaluate the effects of de-escalating doses of d4T on markers associated with HIV infection.
Currently, the only FDA-approved therapy for patients with AIDS or ARC is zidovudine (AZT), a drug with significant value but limited use because of toxic effects on the bone marrow. d4T has not been tested in humans, but it has inhibited the reproduction of HIV (the virus that causes AIDS) in laboratory experiments. In some studies with laboratory animals, d4T was less toxic against blood cells than AZT.
Study Overview
Detailed Description
Currently, the only FDA-approved therapy for patients with AIDS or ARC is zidovudine (AZT), a drug with significant value but limited use because of toxic effects on the bone marrow. d4T has not been tested in humans, but it has inhibited the reproduction of HIV (the virus that causes AIDS) in laboratory experiments. In some studies with laboratory animals, d4T was less toxic against blood cells than AZT.
A maximum tolerated dose (MTD) has been found in Phase I trials to date. An MED will be determined. The daily dose of d4T is divided into 2 portions and administered approximately 12 hours apart for 10 weeks. 5 patients receive the initial dose level and successive groups of 5 patients enter the study at a lower dose level once 3 patients in the preceding group have successfully completed at least 3 weeks of dosing and shown a positive effect on CD4 cell count and p24 antigen levels. The initial group of patients continue dosing at their dose level for an additional 94 weeks as long as they are doing well as measured by p24 antigen levels and CD4 cell counts. The dose de-escalation scheme continues until a lack of efficacy is seen in 2 of 5 patients in any group. Patients are assigned to de-escalating dose level treatment groups in the order in which they are enrolled. Blood and urine samples are taken regularly to check for toxic effects and therapeutic effectiveness. In each dosing group, 3 of 5 patients will be p24 antigen positive greater than or equal to 70 pg/ml, and 2 of 5 patients will have CDC-defined AIDS.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Cornell Univ Med Ctr
-
New York, New York, United States, 10029
- Mount Sinai Med Ctr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis.
- TMP/SMX as an alternative prophylactic agent, 1 DS tablet orally per day.
- Acute therapy with oral acyclovir for herpes simplex infections for no more than 7 days, providing d4t is suspended Symptomatic therapy such as analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy may be administered for toxicities as deemed necessary by the principal investigator. For therapy of fever, aspirin rather than acetaminophen should be used.
Concurrent Treatment:
Allowed:
- Transfusion of up to 2 units of packed red blood cells every 3 weeks for grade 3 or grade 4 anemia (see Recommendations for Grading of Acute and Subacute Toxic Effects (Adults)) until patient returns to baseline from grade 3 or to baseline or grade 1 from grade 4.
Patient must have:
- AIDS or AIDS related complex (CDC Group IVA or CDC Group IVC-2 with thrush or oral leukoplakia).
- Ability to provide informed consent.
- Availability to follow-up for at least 6 months.
- Absence of active, AIDS-defining opportunistic infection on study entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Active, AIDS-defining opportunistic infection.
- Intractable diarrhea.
- History or propensity for seizure disorders requiring anticonvulsants for control.
- Any other clinical condition which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements.
Concurrent Medication:
Excluded:
- Systemic therapy with this or any other antiretroviral drug (including AL-721, ddI, ddC, interferon, immunomodulating drugs) or investigational drug.
- Ribavirin.
- Cytotoxic anticancer therapy.
- Therapy with any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes, such as rifampin or barbiturates.
- Systemic maintenance or chemoprophylaxis for opportunistic infections.
- Trimethoprim / sulfamethoxazole for Pneumocystis carinii infections.
- Acute therapy with ketoconazole for thrush.
- Neurotoxic agents listed in the protocol.
Patients with the following are excluded:
- Previous intolerance to zidovudine (AZT) as demonstrated by transfusion dependent anemia (transfusion required every 3 weeks or less and AZT-related depression of neutrophils to < 500 cells/mm3).
- Life expectancy < 6 months.
Prior Medication:
Excluded:
- Any other prior therapy which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements.
Excluded within 2 weeks of study entry:
- Therapy with any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes, such as rifampin or barbiturates.
Excluded within 1 month of study entry:
- Systemic therapy with this or any other antiretroviral drug (including AL-721, interferon, immunomodulating drugs, ddI, ddC) or any investigational drug.
Excluded within 3 months of study entry:
- Ribavirin.
- Cytotoxic anticancer therapy.
Prior Treatment:
Excluded:
- Any prior therapy which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements.
Preference:
- Tolerating zidovudine (AZT) at time of study entry.
Active alcohol or drug abuse sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: HS Sacks
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- AIDS-Related Complex
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Stavudine
Other Study ID Numbers
- ACTG 089
- AI455-002
- 070V3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Stavudine
-
Groupe Hospitalier Pitie-SalpetriereBristol-Myers SquibbUnknown
-
University of ZimbabweAIDS Care Research in AfricaCompletedHIV Infections | Cryptococcal MeningitisZimbabwe
-
Makerere UniversityDepartment of Foreign Affairs, IrelandCompletedHIV InfectionsUganda
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
University of KwaZuluAIDS Malignancy Consortium; National Research Foundation, Singapore; AIDS Care... and other collaboratorsCompletedHIV | Kaposi's Sarcoma | AIDS | Human Herpesvirus 8South Africa
-
Makerere UniversityUniversity of California, San FranciscoCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States, Puerto Rico, South Africa
-
Bristol-Myers SquibbCompletedHIV InfectionsUnited States, Puerto Rico
-
Bristol-Myers SquibbCompletedHIV Infections | AIDSBelgium, Portugal, Spain, United States, Argentina, Canada, France, Italy, Mexico, Puerto Rico, Singapore, South Africa, Thailand, Russian Federation, Israel, Brazil
-
Boehringer IngelheimCompleted